查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853783

中樞神經系統治療市場依適應症、作用機轉、給藥途徑、最終用戶及通路分類－2025-2032年全球預測

Central Nervous System Therapeutics Market by Indication, Mechanism Of Action, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，中樞神經系統治療市場將成長至 2,550.4 億美元，複合年成長率為 7.48%。

關鍵市場統計數據
基準年2024年 1431.1億美元
預計年份：2025年 1532.5億美元
預測年份 2032 2550.4億美元
複合年成長率 (%) 7.48%

針對不斷發展的中樞神經系統治療生態系統，制定簡潔的策略方向，整合科學進步、監管動態與醫療服務轉型。

中樞神經系統治療生態系統正處於關鍵的十字路口，科學突破、監管創新和醫療服務模式的轉變正在匯聚，重塑藥物研發和商業化進程。分子生物學、載體工程和抗體設計的進步正在加速從症狀治療轉變為緩解疾病療法的轉變。同時，醫療系統正在調整治療路徑，更加重視慢性病管理和居家醫療，這為針對不同給藥途徑和環境最佳化的治療藥物創造了機會和需求。

在此背景下，相關人員必須應對科學機會與營運挑戰之間錯綜複雜的相互作用。生技藥品和基因治療方法潛力巨大，但也增加了生產的複雜性和供應鏈的敏感性。小分子和胜肽類藥物因其廣泛的可及性以及口服和經皮給藥而仍然重要。支付者和醫療服務提供者越來越需要可靠的真實世界證據和基於價值的合約框架，以控制高成本治療創新帶來的預算影響。因此，整合研發重點、生產能力、上市計畫和通路策略的策略觀點對於在維持商業性可行性的同時改善病患療效至關重要。

本執行摘要總結了關鍵的變革促進因素，檢驗了影響該行業的政策和貿易壓力，解讀了市場細分和區域動態，並為致力於將科學前景轉化為永續的臨床和商業性影響的領導者提供了切實可行的建議。分析強調了多學科合作、對循證醫學的投入以及積極主動的供應鏈管理對於中樞神經系統治療領域計畫成功的重要性。

精準治療方式的創新和監管政策的調整將如何改變中樞神經系統藥物的研發、商業化和遞送方式？

中樞神經系統治療領域正經歷變革性的轉變，這主要得益於技術、監管和醫療服務模式的融合。基因療法和單株抗體等精準治療方法正從概念驗證階段走向計畫階段，這需要專門的生產製造、目標患者的精準識別以及新型的醫保報銷機制。同時，血腦障壁調控和遞送平台技術的進步正在拓展可行的分子干涉手段，使能夠以更高的特異性直接作用於中樞神經系統靶點，並可能減少全身性副作用。

醫療服務模式的創新正在重塑醫療服務的提供方式和地點。雖然醫院在急診和複雜疾病的治療中仍然發揮著核心作用，但診所和居家醫療在慢性病和復健期護理管理方面承擔著越來越重要的責任。這種轉變凸顯了給藥途徑設計的重要性－注射與口服或經皮給藥相比，需要不同的物流規劃。

同時，法律規範也在進行調整，以適應高影響力療法的快速核准途徑，並整合新的終點指標和替代標記。監管機構優先考慮強力的安全監測和真實世界證據的生成，這正在影響臨床開發方案和核准後的承諾。同時，相關人員正在加快學術中心、受託製造廠商以及專科藥房之間的合作，以應對複雜性並縮短患者用藥時間。這種變革性的轉變有利於那些能夠將科學敏捷性與營運嚴謹性以及在研發、監管、生產和商業化等各個環節的相關人員合作相結合的機構。

評估不斷變化的貿易壓力和關稅主導的供應鏈應對措施，這些措施正在重塑中樞神經系統藥物的採購、生產和獲取策略。

包括關稅措施在內的政策環境對中樞神經系統治療藥物和器械的原料採購、組件供應以及成本結構有具體的影響。關稅變化可能會加劇依賴特殊原料、單一來源生技藥品成分和複雜生產投入的產業的現有脆弱性。隨著進口活性藥物原料藥、病毒載體和關鍵生產設備的關稅提高，製造商將面臨更高的投入成本，進而對生產計劃、庫存策略以及與支付方和醫療服務提供者的價格談判產生連鎖反應。

2025年關稅的累積影響可能會凸顯那些為了成本效益而犧牲韌性，最佳化全球供應鏈的企業所面臨的策略權衡。為此，許多企業正在評估近岸外包或在地化策略，以降低貿易政策波動帶來的風險。此外，企業也在重新評估其供應商組合，並尋找替代供應商，以實現關鍵試劑和組件來源的多元化。雖然這些調整可以緩解未來的關稅衝擊，但需要嚴格的品質監控和驗證，以確保治療方法的完整性。

對於醫院和診所而言，關稅導致的採購成本增加可能會使預算更加緊張，迫使它們優先考慮具有明確價值主張的治療方法，並實施更嚴格的處方管理。家庭護理服務提供者和分銷管道受到的影響可能因對進口設備和專用包裝的依賴程度而有所不同。整體而言，關稅變化的累積效應將凸顯供應鏈透明度、庫存最佳化以及貫穿採購、居家照護和銷售等各個環節的綜合成本削減策略的重要性。

主導的策略要務，旨在調整管理設定和通路，以適應不同的模式，從而最佳化發展路徑並實現預期成果。

細分領域的細微差別決定了治療開發和商業化活動中的機會窗口和營運要求。基於適應症的研究涵阿茲海默症、注意力不足過動症、憂鬱症、癲癇、多發性硬化症、神經病變疼痛、帕金森氏症和中風，每種疾病都有其獨特的患者識別、終點選擇的複雜性以及與支付方談判的挑戰。阿茲海默症和帕金森氏症計畫著重於緩解疾病和生物標記整合，注意力不足過動症和憂鬱症則優先考慮快速改善症狀和提高依從性，而癲癇和中風干預措施通常與急性期護理和康復路徑交織在一起。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 基因治療方法在治療難治性神經系統疾病的應用日益廣泛
  • 將數位生物標記整合到臨床試驗中，加速中樞神經系統藥物研發
  • 擴大阿茲海默症中澱粉樣蛋白和Tau的單株抗體療法
  • 人們越來越關注藥物基因組學篩檢在個人化憂鬱症和焦慮症管理的應用。
  • 針對帕金森氏症神經發炎路徑的小分子抑制劑數量不斷增加
  • 脊髓內和鼻內給藥平台的進展有助於克服血腦障壁
  • 生物技術新興企業與大型製藥公司建立策略夥伴關係，以實現中樞神經系統產品線多元化策略

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依適應症分類的中樞神經系統藥物市場

  • 阿茲海默症
  • 注意力不足過動症
  • 憂鬱症
  • 癲癇
  • 多發性硬化症
  • 神經病變疼痛
  • 帕金森氏症
  • 中風

9. 依作用機轉分類的中樞神經系統治療藥物市場

  • 基因治療
  • 單株抗體
  • 胜肽
  • 小分子

第10章：依給藥途徑分類的中樞神經系統藥物市場

  • 注射
  • 口服
  • 經皮

第11章：按最終用戶分類的中樞神經系統藥物市場

  • 診所
  • 居家照護
  • 醫院

12. 中樞神經系統藥物市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥局

13. 各地區中樞神經系統藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 中樞神經系統藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國中樞神經系統藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Johnson & Johnson
    • Roche Holding AG
    • Novartis AG
    • Pfizer Inc.
    • Biogen Inc.
    • Merck & Co., Inc.
    • AbbVie Inc.
    • Eli Lilly and Company
    • Teva Pharmaceutical Industries Ltd.
    • Otsuka Pharmaceutical Co., Ltd.
Product Code: MRR-02026C4C9A19

The Central Nervous System Therapeutics Market is projected to grow by USD 255.04 billion at a CAGR of 7.48% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 143.11 billion
Estimated Year [2025] USD 153.25 billion
Forecast Year [2032] USD 255.04 billion
CAGR (%) 7.48%

A concise strategic orientation to the evolving central nervous system therapeutics ecosystem that integrates scientific advances regulatory dynamics and care delivery transformations

The central nervous system therapeutics ecosystem is at a pivotal juncture where scientific breakthroughs, regulatory innovation, and shifting care delivery models converge to reshape development and commercialization pathways. Advances in molecular biology, vector engineering, and antibody design have accelerated the transition from symptomatic therapies toward disease-modifying approaches, while an expanding set of digital and diagnostic tools is improving patient identification and outcome measurement. At the same time, health systems are recalibrating care pathways to emphasize chronic disease management and home-based care, creating opportunities and demands for therapies optimized for different administration routes and settings.

Against this backdrop, stakeholders must navigate a complex interplay of scientific opportunity and operational challenge. Biologics and gene-based modalities bring high potential but also elevated manufacturing complexity and supply chain sensitivity. Small molecules and peptides remain important for broad accessibility and oral and transdermal delivery. Payers and providers are increasingly seeking robust real-world evidence and value-based contracting frameworks to manage the budgetary implications of high-cost therapeutic innovations. Therefore, a strategic perspective that integrates R&D priorities, manufacturing capabilities, market access planning, and channel strategies is essential for advancing patient outcomes while maintaining commercial viability.

This executive summary synthesizes the critical drivers of change, examines policy and trade pressures affecting the industry, interprets segmentation and regional dynamics, and proposes actionable recommendations for leaders aiming to translate scientific promise into sustainable clinical and commercial impact. The analysis emphasizes the importance of multidisciplinary coordination, investment in evidence generation, and proactive supply chain management as core enablers for successful programs in the central nervous system therapeutic domain.

How precision modalities delivery innovations and regulatory adaptations are collectively transforming development commercialization and care delivery in CNS therapeutics

The landscape of central nervous system therapeutics is undergoing transformative shifts driven by converging technological, regulatory, and care delivery trends. Precision modalities such as gene therapy and monoclonal antibodies have matured from proof-of-concept into program phases that demand specialized manufacturing, targeted patient identification, and novel reimbursement constructs. Concurrently, advances in blood-brain barrier modulation and delivery platforms are expanding the range of feasible molecular interventions, enabling treatments that directly engage central nervous system targets with greater specificity and potentially fewer systemic effects.

Care delivery innovations are reshaping where and how therapies are administered. Hospitals continue to play a central role for acute and complex procedures, while clinics and home care settings are assuming greater responsibility for chronic management and post-acute therapy administration. This shift increases the importance of administration route design-injectable formulations require different logistical planning than oral or transdermal therapies-and places a premium on patient-friendly delivery systems and telehealth-enabled monitoring to maintain adherence and safety.

Meanwhile, regulatory frameworks are adapting to accommodate expedited pathways for high-impact therapies and to integrate novel endpoints and surrogate markers. Regulators are emphasizing robust safety monitoring and real-world evidence generation, which affects clinical development design and post-approval commitments. In parallel, stakeholders are accelerating collaboration across academic centers, contract development and manufacturing organizations, and specialty pharmacies to manage complexity and speed time to patient. These transformative shifts collectively favor organizations that can integrate scientific agility with operational rigor and stakeholder alignment across R&D, regulatory, manufacturing, and commercialization functions.

Assessment of evolving trade pressures and tariff-driven supply chain responses that are reshaping procurement manufacturing and access strategies across CNS therapeutics

The policy environment, including tariff actions, has tangible implications for ingredient sourcing, component supply, and the cost profile of therapeutics and devices used in central nervous system care. Tariff changes can amplify existing vulnerabilities in a sector that is reliant on specialized raw materials, single-source biologics components, and advanced manufacturing inputs. When duties increase on imported active pharmaceutical ingredients, viral vectors, or key manufacturing equipment, manufacturers face higher input costs that cascade through production schedules, inventory strategies, and pricing conversations with payers and providers.

Cumulative tariff impacts in 2025 are likely to accentuate strategic trade-offs for firms that have optimized global supply chains for cost-efficiency rather than resilience. In response, many organizations are evaluating nearshoring or regionalization strategies to reduce exposure to trade policy volatility, which can improve lead-time predictability but may require significant capital investment in local manufacturing capabilities. In addition, companies are reassessing supplier portfolios and qualifying alternative vendors to diversify sources for critical reagents and components. These adjustments can mitigate future tariff shocks but demand rigorous quality oversight and validation to preserve therapeutic integrity.

For hospitals and clinics, increased procurement costs driven by tariffs may translate into tighter budgetary pressure, prompting prioritization of therapies with clear value propositions and implementation of stricter formulary controls. Home care providers and distribution channels may be affected differently depending on their dependence on imported devices or specialty packaging. Overall, the cumulative effect of tariff changes is to elevate the importance of supply chain transparency, inventory optimization, and integrated cost mitigation strategies across procurement, manufacturing, and commercial functions.

Segment-driven strategic imperatives that align indication modality administration setting and distribution pathways to optimize development pathways and access outcomes

Segment-level nuances define opportunity windows and operational requirements across therapeutic development and commercialization activities. Based on Indication, studies cross Alzheimer's Disease, Attention Deficit Hyperactivity Disorder, Depression, Epilepsy, Multiple Sclerosis, Neuropathic Pain, Parkinson's Disease, and Stroke, each presenting unique patient identification challenges, endpoint selection complexities, and payer negotiations. Alzheimer's and Parkinson's programs emphasize disease modification and biomarker integration, ADHD and depression prioritize rapid symptomatic benefit and adherence, while epilepsy and stroke interventions often intersect with acute care delivery and rehabilitation pathways.

Based on Mechanism Of Action, the landscape includes Gene Therapy, Monoclonal Antibodies, Peptides, and Small Molecules, which impose distinct development and manufacturing footprints. Gene therapies demand expertise in vector design, cold-chain logistics, and long-term safety monitoring. Monoclonal antibodies require biologics manufacturing capacity and specialized distribution, whereas peptides and small molecules typically offer advantages in oral or transdermal delivery and generally lower manufacturing complexity, supporting broader access models.

Based on Route Of Administration, injectable, oral, and transdermal approaches create differentiated adoption and adherence profiles. Injectable modalities often align with clinic or hospital administration and can command premium reimbursement when paired with durable outcomes, whereas oral and transdermal therapies support outpatient and home care use, improving convenience but requiring strong adherence support programs. Based on End User, clinics, home care, and hospitals exhibit distinct procurement behaviors and clinical workflows, necessitating tailored training, support, and supply strategies for each setting. Based on Distribution Channel, hospital pharmacies, online pharmacies, and retail pharmacies represent varied access touchpoints that influence unit economics, patient experience, and channel-specific compliance and storage requirements.

Taken together, segmentation insights emphasize the imperative of aligning modality selection with end-user workflows, delivery route preferences, and distribution capabilities, while simultaneously addressing manufacturing constraints and evidence generation needs that differ markedly by indication and mechanism of action.

How regional regulatory ecosystems commercial infrastructures and supply chain strategies collectively influence development prioritization and global rollout planning

Regional dynamics shape development partnerships, regulatory strategies, and commercial entry sequencing in meaningful ways. The Americas region exhibits a strong ecosystem for clinical trial infrastructure, venture financing, and advanced biomanufacturing capacity, supporting the progression of high-complexity modalities and early commercialization of innovative therapies. Regulatory engagement and payer negotiations in this region require substantial evidence of clinical benefit and cost-effectiveness aligned with health system priorities.

Europe Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where centralized approval pathways coexist with national-level payer determinations. This variability necessitates flexible pricing and market access strategies, strong real-world evidence generation, and sometimes staggered launch approaches to accommodate divergent health technology assessment requirements and procurement practices.

Asia-Pacific includes both advanced markets with growing biotech capabilities and emerging markets with rapidly expanding access to specialty care. This region offers strategic opportunities for regional manufacturing partnerships, patient recruitment for diverse trial populations, and alternative pricing strategies to expand access. Across all regions, regionalization of supply chains, local regulatory intelligence, and culturally attuned patient engagement approaches are crucial to converting scientific advances into measurable health impacts and sustainable commercial returns.

Profiles of organizational differentiation driven by platform integration manufacturing strategies partnership models and evidence generation excellence

Leading organizations are differentiating through integrated platform capabilities, strategic alliances, and capability-building investments that address the unique demands of central nervous system therapeutics. Companies with vertically integrated biologics and gene therapy production resources are accelerating program timelines by reducing dependence on third-party capacity, while others prioritize partnerships with specialized contract developers and manufacturers to scale modal-specific production. In parallel, firms that invest in translational science, biomarker development, and companion diagnostics are improving patient selection and demonstrating clearer value propositions to payers and providers.

Commercial differentiation is also emerging through service-oriented strategies that support therapy delivery across varied care settings. Companies offering training programs for clinics and home care providers, bundled patient support services, and digital adherence tools are enhancing uptake and persistence, particularly for therapies requiring ongoing administration or complex monitoring. In the face of supply chain and tariff pressures, organizations that proactively diversify supplier networks, invest in quality oversight, and establish multi-regional manufacturing footprints are better positioned to maintain continuity of supply and negotiate with payers from a position of strength.

Finally, the most resilient players are executing disciplined evidence strategies that integrate randomized trial data with real-world outcomes and health economic modeling, enabling more compelling discussions with payers and health systems. This holistic approach-combining scientific innovation, manufacturing robustness, and tailored commercialization services-defines current leadership in the CNS therapeutics domain.

Practical prioritized actions for leaders to strengthen resilience adapt commercialization and accelerate patient access while preserving innovation momentum

Industry leaders should prioritize a set of pragmatic actions that balance innovation with operational resilience. First, invest in platform and delivery technologies that reduce dependency on single suppliers and enable flexible administration across hospitals clinics and home care settings. Second, accelerate investments in translational biomarkers and companion diagnostics to sharpen patient selection and improve the probability of meaningful clinical outcomes, thereby strengthening pricing and reimbursement discussions.

Third, restructure supply chain strategies to emphasize diversification and regional capacity, pairing nearshoring options with qualified contingency suppliers for critical reagents, viral vectors, and specialized components. Fourth, expand commercial services that facilitate adoption in non-traditional settings by developing training programs for clinicians, remote monitoring solutions, and patient support offerings that address adherence and safety in outpatient contexts. Fifth, adopt an integrated evidence strategy that blends rigorous clinical trial design with real-world evidence collection and economic modeling to support value-based contracting and formulary inclusion.

Finally, cultivate strategic partnerships across academia, contract manufacturing organizations, and specialty pharmacies to accelerate development and distribution while sharing risk. Implementing these prioritized actions will help organizations manage tariff volatility, operational complexity, and payer expectations while sustaining clinical innovation and improving patient access.

A multi-method research framework combining expert interviews literature synthesis segmentation mapping and scenario analysis to validate operationally relevant insights

The research approach combined qualitative and quantitative methods to ensure robustness and triangulation of findings. Primary inputs included structured interviews with clinical investigators health system leaders manufacturing and supply chain executives and commercial strategists to capture operational realities and emergent practice patterns. Secondary research encompassed peer-reviewed scientific literature, regulatory guidance documents, technical manufacturing publications, and policy analyses to inform understanding of modality-specific technical requirements and regulatory trajectories.

Analytical steps comprised segmentation mapping to reconcile indication, mechanism of action, route of administration, end-user, and distribution channel implications for development and commercialization strategies. Regional assessment applied regulatory and health system intelligence to contextualize market entry sequencing and supply chain design. Scenario analysis was used to evaluate the potential operational consequences of tariff adjustments and supply chain disruptions, informing recommendations for diversification and capacity investment.

Key limitations include variability in publicly available clinical outcome data across indications and the rapid evolution of regulatory guidance for novel modalities. To mitigate these constraints, findings were cross-validated with subject matter experts and supplemented by case examples of recent product launches and manufacturing scale-up programs to derive practical implications for decision-makers.

Concluding synthesis linking scientific advances regulatory and supply chain considerations to actionable strategic priorities for sustained clinical and commercial impact

In summary, central nervous system therapeutics occupy a dynamic space where scientific potential and operational complexity coexist. Progress in gene therapy, monoclonal antibodies, and advanced delivery platforms offers genuine potential to address unmet neurological needs, yet achieving clinical and commercial success requires an integrated strategy that spans translational science, manufacturing capability, supply chain resilience, and payer engagement. The interplay between administration routes and care settings underscores the need to design therapies and support services that fit clinic hospital and home care workflows to maximize uptake and adherence.

Policy and trade developments, including tariff changes, further emphasize the importance of proactive supply chain diversification, regional manufacturing investments, and flexible commercialization pathways. Regional differences in regulatory and reimbursement environments demand tailored approaches that align evidence generation, pricing strategies, and distribution planning with local stakeholder expectations. Companies that combine scientific differentiation with disciplined operational planning and targeted evidence strategies will be best positioned to convert innovation into sustained clinical impact and accessible care.

Ultimately, success in this sector depends on multidisciplinary coordination and the capacity to evolve organizational models in response to technological advances and external pressures, thereby delivering meaningful patient outcomes while preserving long-term commercial viability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of gene therapy modalities for treatment-resistant neurological disorders
  • 5.2. Integration of digital biomarkers into clinical trials to accelerate CNS drug development
  • 5.3. Expansion of monoclonal antibody therapies targeting amyloid and tau in Alzheimer's disease
  • 5.4. Growing focus on pharmacogenomics screening for personalized depression and anxiety management
  • 5.5. Increase in small molecule inhibitors addressing neuroinflammation pathways in Parkinson's disease
  • 5.6. Advancement of intrathecal and intranasal delivery platforms to overcome blood-brain barrier hurdles
  • 5.7. Strategic partnerships between biotech startups and big pharma for CNS pipeline diversification strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Central Nervous System Therapeutics Market, by Indication

  • 8.1. Alzheimer's Disease
  • 8.2. Attention Deficit Hyperactivity Disorder
  • 8.3. Depression
  • 8.4. Epilepsy
  • 8.5. Multiple Sclerosis
  • 8.6. Neuropathic Pain
  • 8.7. Parkinson's Disease
  • 8.8. Stroke

9. Central Nervous System Therapeutics Market, by Mechanism Of Action

  • 9.1. Gene Therapy
  • 9.2. Monoclonal Antibodies
  • 9.3. Peptides
  • 9.4. Small Molecules

10. Central Nervous System Therapeutics Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Transdermal

11. Central Nervous System Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Central Nervous System Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Central Nervous System Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Central Nervous System Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Central Nervous System Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Johnson & Johnson
    • 16.3.2. Roche Holding AG
    • 16.3.3. Novartis AG
    • 16.3.4. Pfizer Inc.
    • 16.3.5. Biogen Inc.
    • 16.3.6. Merck & Co., Inc.
    • 16.3.7. AbbVie Inc.
    • 16.3.8. Eli Lilly and Company
    • 16.3.9. Teva Pharmaceutical Industries Ltd.
    • 16.3.10. Otsuka Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 258. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 259. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 280. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 281. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 282. BRICS CEN